Cecilia Pessoa Gingerich

Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.

In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.

Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.

Results from the phase 3 IMMhance study show that of patients who reached sPGA 0 at week 28, 73% maintained skin clearance at week 94.

Patients with plaque psoriasis taking apremilast, etanercept, and ustekinumab had a lower rate of serious infections than those who took methotrexate.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

The expanded indication allows the use of intravenous belimumab (Benlysta) in children as young as 5 years of age.

Risankizumab (Skyrizi) is now approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

The COAST-X trial evaluated the safety and efficacy of ixekizumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA).

The study also found that the overall rate of cardiovascular events was low in the study population, indicating that statins aren’t required for all RA patients.

Certolizumab pegol (Cimzia) is the first FDA-approved treatment for the condition.

Two studies of baricitinib monotherapy for adults with moderate to severe atopic dermatitis met primary efficacy endpoints.

The immunosuppressive drug was more effective and resulted in fewer adverse events in patients with psoriasis but without psoriatic arthritis.

ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.

Madelaine A. Feldman, MD, touches on new developments in rheumatology including JAK inhibitor research, genetics and epigenetics, and personalized medicine.

Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

The updated label includes safety and efficacy data about the use of rituximab as follow-up treatment for patients with granulomatosis with polyangiitis and microscopic polyangiitis.

Data from 2 phase 3 studies of secukinumab (Cosentyx) in patients with psoriatic arthritis and ankylosing spondylitis will be presented at an upcoming meeting.

A subcutaneous formulation of tocilizumab (Actemra) is now approved for the treatment of active systemic juvenile idiopathic arthritis in patients at least 2 years old.

At 12 weeks, patients with rheumatoid arthritis receiving filgotinib responded and achieved low disease activity at significantly higher rates compared to placebo.

The rare condition affects the skin and can lead to ulceration and scarring, however, there are currently no FDA approved treatments for necrobiosis lipoidica.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

After rejecting the drug in 2017, the FDA approved the 2 mg dose of baricitinib (Olumiant) for adults with moderate to severe rheumatoid arthritis.